Abbott LaboratoriesABT
ASignal's systematic analysis rates ABT as Neutral.
Reflects the latest available analysis · analyzed Sep 1, 2026
The case on ABT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin of 56.85% indicating pricing power
- Free cash flow of $7.21B supports financial flexibility
- Debt-to-equity ratio of 0.63x is within moderate range
- Revenue growth of 13.00% indicates solid top-line expansion
- Forward P/E of 18.20x suggests better valuation ahead
- Negative earnings growth of -47.50% YoY
- MACD below signal line indicating weakening momentum
- Negative price momentum trend
- High PEG ratio of 2.25x suggesting overvaluation relative to growth
- Quick ratio of 0.80x indicates potential short-term liquidity concerns
Peers
Clustered with ABT by analysis-profile similarity.
See the full verdict on ABT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ABT
Most investors never get a second opinion, let alone several. ASignal runs ABT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.